Integer Holdings Corporation

Integer Holdings Corporation (ITGR) Market Cap

Integer Holdings Corporation has a market capitalization of $3.10B.

Financials based on reported quarter end 2025-12-31

Price: $90.20

1.83 (2.07%)

Market Cap: 3.10B

NYSE · time unavailable

CEO: Payman Khales

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2000-09-29

Website: https://www.integer.net

Integer Holdings Corporation (ITGR) - Company Information

Market Cap: 3.10B · Sector: Healthcare

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Analyst Sentiment

70%
Buy

Based on 10 ratings

Analyst 1Y Forecast: $105.67

Average target (based on 2 sources)

Consensus Price Target

Low

$82

Median

$98

High

$133

Average

$103

Potential Upside: 13.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 INTEGER HOLDINGS CORP (ITGR) — Investment Overview

🧩 Business Model Overview

Integer Holdings Corporation (NYSE: ITGR) is a leading medical device outsourcing (MDO) manufacturer, specializing in advanced medical device technologies and enabling novel therapeutic solutions for the world’s largest medtech OEMs (original equipment manufacturers). With a global manufacturing footprint and a deeply integrated supply chain, Integer designs and manufactures medical device components, subassemblies, and finished devices for markets such as interventional cardiology, neuromodulation, cardiac rhythm management, and portable medical devices. The company’s model focuses on long-term, collaborative relationships with medical device companies, leveraging engineering expertise, regulatory compliance, and operational efficiency. Integer plays a critical role in its customers’ innovation pipelines by bringing products from concept to commercialization—often under complex regulatory environments—enabling healthcare advancements without the OEMs bearing the burden of in-house manufacturing.

💰 Revenue Streams & Monetisation Model

Integer’s business structure generates revenue primarily through contract manufacturing, component sales, and value-added design, development, and engineering services. Revenue streams are segmented by end-markets, typically including cardiovascular, neuromodulation, cardiac rhythm management, and portable medical equipment. The company maintains longstanding contracts with major OEMs, often structured as multi-year supply agreements, which contribute recurring revenues and predictability. Integer’s monetization also includes fees for early-stage prototyping, co-development partnerships, and technology licensing, particularly when co-designing next-generation devices with OEM partners. These diversified streams provide a stable base, supported further by cross-selling opportunities across its broader manufacturing ecosystem.

🧠 Competitive Advantages & Market Positioning

Integer possesses durable competitive advantages rooted in technical know-how, IP portfolio, regulatory expertise, and operational scale. Its deep engineering talent enables complex product solutions, such as batteries and precision components for implantables—an important barrier to entry, given the highly specialized nature of medical device manufacturing. The company’s broad certifications (including ISO, FDA, and international equivalents) reinforce its reputation as a reliable and compliant partner. With manufacturing facilities strategically located across North America, Europe, Asia, and Latin America, Integer achieves proximity to global OEMs, supporting logistical agility and cost efficiency. Furthermore, the company’s end-to-end solutions—from design to finished product—position it as a strategic partner rather than a commoditized supplier. This unique value proposition secures preferred supplier status with several top-tier medical device firms.

🚀 Multi-Year Growth Drivers

Several secular and company-specific factors underpin Integer’s growth outlook: - **Healthcare Innovation**: Rising prevalence of chronic diseases and aging demographics are driving demand for advanced therapies, such as neuromodulation and structural heart interventions—markets that Integer serves comprehensively. - **OEM Outsourcing Trends**: Medical device companies continue to outsource manufacturing to reduce capital intensity, accelerate innovation, and focus on core competencies. Integer is particularly well-positioned to capture incremental outsourcing as devices become smaller, more complex, and increasingly regulated. - **New Product Introductions**: The push for minimally invasive procedures and next-generation devices opens cross-selling and up-selling opportunities, especially as Integer becomes involved in early-stage co-development. - **Geographic Expansion**: Emerging markets offer considerable growth potential for medical devices. Integer’s global presence is a platform for expanding with multinational OEMs and responding to localized demand. - **Operational Excellence and Portfolio Optimization**: Ongoing investments in operational efficiency, supply chain resilience, and the transition toward higher-margin products support outperformance versus pure-play contract manufacturers.

⚠ Risk Factors to Monitor

Several risks merit close attention: - **Customer Concentration**: Integer relies on a limited number of large OEMs for a significant portion of its sales. A loss or delay of business from any large customer could meaningfully impact results. - **Regulatory Environment**: The stringent and evolving regulatory requirements for medical devices globally create compliance risks, potential delays in approvals, and increased operational costs. - **Pricing Pressure and Commoditization**: As large OEMs seek cost efficiencies, increased pricing pressures or commoditization of basic components could impact margins. - **Supply Chain Disruption**: Reliance on global supply networks exposes Integer to risk from raw material shortages, geopolitical developments, or logistical challenges. - **Intellectual Property**: While Integer has robust IP assets, litigation risk remains, and breaches could compromise competitive advantages.

📊 Valuation & Market View

Within the medtech supply chain sector, Integer Holdings is valued as a premium outsourcing partner, often trading at multiples comparable to or above broader contract manufacturers, reflecting superior margins, growth, and industry positioning. Investors assess Integer through peer and historical benchmarks, factoring enterprise value-to-EBITDA and price-to-earnings ratios, as well as growth potential compared to sector indices. The company’s recurring revenue base, strong free cash flow generation, and exposure to high-growth medtech segments contribute to its premium valuation. Analysts also focus on organic revenue growth, margin expansion opportunities, acquisitions, and capital allocation discipline. Integer’s end-market mix, long-term contracts, and sticky relationships with blue-chip OEMs underpin the consensus that it warrants a valuation premium among contract manufacturers.

🔍 Investment Takeaway

Integer Holdings is strategically positioned as an industry-leading medical device manufacturer, offering unique value through its technical expertise, regulatory compliance, and global manufacturing reach. The company captures tailwinds from healthcare innovation, increased OEM outsourcing, and the push for minimally invasive, next-generation medical devices. While risks exist—primarily customer concentration, regulatory hurdles, and potential supply chain challenges—Integer’s track record, deep relationships with major OEMs, and ability to innovate on behalf of partners provide meaningful moats. For investors seeking exposure to the structural growth of the medtech sector, coupled with defensible margins and a resilient business model, Integer offers a compelling platform for steady, long-term value creation.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"ITGR reported revenue of $472.06M for the year ending December 31, 2025, with a net income of $48.61M and earnings per share (EPS) of $1.39. The company's balance sheet shows total assets of $3.41B and total liabilities of $1.66B, resulting in total equity of $1.75B and a net debt of about $1.38B. The operating cash flow was $55.42M, indicating a free cash flow of $27.94M after capital expenditures of $27.48M. Despite a year-to-date price change of 12.26%, the stock has declined by 26.45% over the past year, reflecting current market challenges. With no dividends paid and a focus on reinvestment, the firm's shareholder returns have been primarily driven by price appreciation rather than cash returns. Investors should consider these factors when evaluating the overall risk and potential future performance of the company."

Revenue Growth

Neutral

Solid revenue at $472.06M but growth dynamics not specified.

Profitability

Positive

Positive net income of $48.61M suggests competent profit management.

Cash Flow Quality

Fair

Positive free cash flow of $27.94M indicates reasonable cash generation.

Leverage & Balance Sheet

Neutral

Leverage is moderate, with net debt at $1.38B against $1.75B equity.

Shareholder Returns

Caution

Negative price change over the last year limits shareholder returns despite YTD gain.

Analyst Sentiment & Valuation

Fair

Consensus price target suggests moderate future growth potential.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management delivered 2025 upside (Q4 adjusted EPS $1.76, +23% YoY; full-year adjusted EPS $6.40, +21%; operating margin +74/76 bps in Q4/full-year), and reiterated confidence in a 2027 return to 200 bps above-market organic growth. However, the Q&A pressure points were clearly about 2026 near-term fragility: (1) Q1 operating margin is expected to be down 200–250 bps YoY due to fixed-cost absorption at lower sales/volume, despite “no structural changes”; and (2) DSO looks stretched at end of Q4 because management intentionally limited factoring to use cash for debt flexibility rather than immediate factoring-driven acceleration. On top of this, the core guidance headwind remains the 3%–4% impact from three new products (2 EP, 1 neuromodulation) that had been ~6% of 2025 sales but are expected to be significantly lower in 2026. Overall tone: confident long-term, but quarter-to-quarter execution risk is elevated.

AI IconGrowth Catalysts

  • Return to above-market organic sales growth in 2H 2026 excluding the 3 new-product headwind
  • 2027 target to deliver 200 basis points above market organic sales growth
  • Margin expansion progression expected in 2026 with return in 2H 2026 (fixed-cost absorption as volumes normalize)

Business Development

  • PMA/neuro-domination grouping: engaged with ~40 customers across development phases (launch-phase ramp tied to regulatory/mfg transitions)
  • Three new products referenced as headwind: two in electrophysiology and one in neuromodulation (company remains the supplier; adoption lower than anticipated)

AI IconFinancial Highlights

  • Q4 2025 sales: $472M (+5% reported, +2% organic)
  • Q4 2025 adjusted EPS: $1.76 (+23% YoY) at high end of October outlook range
  • Q4 2025 adjusted operating margin: +74 bps to 17.6% (primarily gross margin improvement)
  • Full-year 2025 sales: $1.854B (+8% reported, +6% organic); adjusted EPS: $6.40 (+21% YoY)
  • Full-year 2025 adjusted operating margin: +76 bps to 17.3%
  • Full-year adjusted effective tax rate: 17.2% (down from 18.3% prior year); tax benefits from R&D investment, lower interest expense, stock-based comp; higher FX partially offset
  • 2026 outlook (reported): -1% to +1%; organic: flat to +3% (midpoint maintained vs October, but high-end narrowed)
  • 2026 outlook headwind: 3% to 4% from three new products representing ~6% of 2025 sales; management expects these to be significantly lower in 2026
  • 2026 adjusted operating income: $304M to $324M (-5% to +1%) and adjusted EBITDA: $391M to $415M (-3% to +3%)
  • 2026 adjusted EPS: $6.29 to $6.78 (-2% to +6%)
  • Q1 2026 operating margin pressure: -200 to -250 bps YoY (driven by fixed-cost absorption challenges at lower volumes)

AI IconCapital Funding

  • Q4 2025 share repurchase: $50,000,000
  • Accelerated share repurchase announced: approximately $50,000,000 under existing authorization
  • 2025 board authorization (context): up to $200,000,000 (November authorization)
  • Cash flow: Q4 2025 CFO $55M; CapEx $27M; Q4 free cash flow $28M
  • Full-year 2025 CFO $196M (down $9M YoY); CapEx $91M (~5% of sales); full-year free cash flow $105M (up $5M YoY)
  • Net total debt (end of Q4 2025): $1.190B; leverage: 3.0x trailing four-quarter adjusted EBITDA (midpoint of 2.5x–3.5x target)
  • 2026 year-end net total debt guide: $1.170B to $1.190B (accelerated repurchase impact)

AI IconStrategy & Ops

  • No structural organization changes planned in 2026 despite volume/headwind; cost structure aligned to expected manufacturing volumes
  • ERP modernization program launched (multiyear) to modernize systems, improve productivity/working capital, accelerate time to market
  • Integer Production System / lean framework continues; continuous improvement focus to support margin expansion
  • Manufacturing footprint expansion referenced earlier in remarks (Salem, VA laser processing/micromachining; Alden, NY expansion for CRM/neuromodulation implants)

AI IconMarket Outlook

  • 2026 sales: reported $1.826B–$1.876B (-1% to +1% reported); organic flat to +3%
  • 2026 organic growth split: low single-digit decline in 1H expected; return to market growth in 2H
  • 2026 sales cadence: nominal ramp sequentially after flat-to-down low single digits in Q1; commentary on production-day impacts (5% tailwind in Q1, 5% headwind in Q4)
  • 2026 adjusted operating income margin: explicitly guided to -200 to -250 bps YoY pressure in Q1; improvement thereafter with return to margin expansion in 2H
  • 2026 operating tax rate assumption: adjusted effective tax rate 16%–18% (Q1 slightly above full-year rate)

AI IconRisks & Headwinds

  • Three new products adoption risk: 3% to 4% headwind to 2026 organic results; management expects these products to be significantly lower in 2026 (2 electrophysiology, 1 neuromodulation); represented nearly 6% of 2025 sales
  • Fixed-cost absorption risk in low-volume periods: guided -200 to -250 bps YoY operating margin pressure in Q1 2026
  • Lowering high-end of sales outlook range: analyst asked for incremental reason; management stated no specific customer forecast changes—guidance tightened around midpoint (implying no new identifiable single customer shortfall)
  • Working-capital/cash actions affecting DSO: management reduced Q4 2025 accounts receivable factoring to preserve financial flexibility (revolver paid down; factoring cash would have been used to prepay Term Loan A), which raised DSO vs typical

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the ITGR Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (ITGR)

© 2026 Stock Market Info — Integer Holdings Corporation (ITGR) Financial Profile